China's Brii Biosciences rises on progress of HBV therapy

Brii Biosciences

07/09/2023 05:22

** Shares of Brii Biosciences  2137.HK  jump as much as
16.2% to HK$3.16, highest since Aug. 17; on course to snap two
consecutive sessions of decline
    ** Stock is fifth biggest pct gainer in Hang Seng Composite
Index  .HSCI  
    ** Beijing-based biotechnology firm says topline cohort
level from interim analysis of Phase 2 study of BRII-179
(VBI-2601) for treatment of chronic hepatitis B was generally
safe while studies evaluating BRII-835 (VIR-2218) are also
promising 
    ** BRII-179 is an add-on therapy for the treatment of
chronic hepatitis B virus infection (HBV)
    ** Hang Seng Commerce & Industry Index  .HSNC  falls 1.2%
and healthcare index  .HSCIH  eases 1.3%
    ** Hang Seng Composite Index  .HSCI  and Hang Seng Index
 .HSI  both dip 1%
    ** As of last close, the stock had dropped 63.1% so far this
year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))